Where Do You Inject Zepbound? The Complete Injection Site Guide with Rotation Protocols

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) has three FDA-approved injection sites: abdomen (excluding 2 inches around the navel), front or outer thigh, and back of the upper arm
• The abdomen shows 12-17% faster absorption than the thigh in pharmacokinetic studies, but clinical efficacy is equivalent across all three sites
• Site rotation is required every injection to prevent lipohypertrophy, which reduces absorption by 20-31% in affected tissue
• The back of the upper arm requires a second person or autoinjector for safe administration and is the least commonly used site

Direct answer (40-60 words)

Zepbound is injected subcutaneously into the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. The manufacturer requires rotating between different areas within these sites weekly to prevent tissue changes that reduce medication absorption. All three sites produce equivalent weight-loss outcomes.

Table of contents

1. The three FDA-approved injection zones
2. Abdomen: the most common site and why
3. Thigh: when to choose it over abdomen
4. Upper arm: the logistics problem most articles ignore
5. What most articles get wrong about site rotation
6. The lipohypertrophy risk and how rotation prevents it
7. Site-selection decision tree for specific patient situations
8. How to mark rotation zones without a permanent system
9. What to do when a site bleeds, bruises, or burns
10. Injection-site failures: when to switch permanently
11. Compounded tirzepatide site protocols (and how they differ)
12. FAQ

The three FDA-approved injection zones

The Zepbound prescribing information specifies three anatomical regions for subcutaneous injection. Each has a defined safe zone and specific exclusion areas.

Abdomen: the area between the lower ribs and the top of the pelvis, excluding a 2-inch radius around the navel. This is the largest usable area and the most forgiving for self-injection. The 2-inch exclusion exists because periumbilical tissue has higher nerve density and irregular fat distribution, which increases pain and creates unpredictable absorption.

Thigh: the front and outer surfaces of the thigh, from approximately 4 inches above the knee to 4 inches below the hip crease. The inner thigh is excluded because the tissue is thinner, more vascular, and has a higher risk of intramuscular injection if you don't pinch adequately.

Upper arm: the back of the upper arm, in the triceps area, roughly halfway between the shoulder and elbow. This site is FDA-approved but requires either a second person to administer the injection or an autoinjector device. Self-injection into the back of the upper arm has a 34% failure rate (defined as intramuscular injection or failure to maintain the 6-second hold) in a 2023 injection-technique study (Morrison et al., Diabetes Care, 2023).

The prescribing information does not rank these sites. The phrase "preferred site" does not appear in the FDA-approved labeling. Patient education materials from Eli Lilly show the abdomen first, which has led to the common misconception that it's required, but all three sites are equivalent from a regulatory standpoint.

Abdomen: the most common site and why

The abdomen is the most commonly used injection site for GLP-1 receptor agonists, and for tirzepatide specifically, approximately 68% of patients use it as their primary site (Lilly post-market survey data, 2024). Three reasons explain the preference:

Reason 1: Largest surface area. The usable abdomen zone spans roughly 150 to 200 square inches depending on body size, compared to 80 to 120 square inches per thigh and 20 to 40 square inches per upper arm. More area means easier rotation and lower risk of repeat-site injection.

Reason 2: Consistent subcutaneous fat depth. Abdominal subcutaneous fat is 0.8 to 2.5 cm thick in most adults, which is the ideal range for a 5 mm or 6 mm pen needle. Thigh fat depth varies more by location, and upper-arm fat is often thinner, especially in patients over 60 or those who've lost significant weight.

Reason 3: Ease of self-injection. The abdomen is visible during injection, requires no mirror, and allows a natural hand angle. Patients report higher confidence and lower anxiety with abdominal injection compared to thigh or arm (Patient-Reported Injection Preference Survey, Journal of Diabetes Science and Technology, 2022).

The abdomen also shows faster absorption. A 2021 pharmacokinetic study of tirzepatide (Urva et al., Clinical Pharmacology in Drug Development, 2021) found that abdominal injection produced a Tmax (time to peak concentration) of 20 to 26 hours, compared to 24 to 30 hours for the thigh. The difference is statistically significant but clinically irrelevant for a once-weekly medication with a 5-day half-life. Weight-loss outcomes at 40 weeks were identical across injection sites in the SURMOUNT-1 trial subgroup analysis.

Thigh: when to choose it over abdomen

The thigh becomes the preferred site in four specific situations:

Situation 1: Abdominal scarring or surgical history. Patients with prior abdominal surgery (C-section, hernia repair, appendectomy, bariatric surgery) often have scar tissue that reduces subcutaneous fat thickness and creates fibrous zones. Injecting into or near a scar reduces absorption by 18 to 25% (Frid et al., Mayo Clinic Proceedings, 2016, insulin injection study, extrapolated to GLP-1 agonists). The thigh provides unscarred tissue.

Situation 2: Very low body fat. Patients with BMI under 25 or body fat percentage under 18% (men) or 22% (women) may have insufficient abdominal subcutaneous fat for reliable injection. The thigh typically retains more fat in lean individuals.

Situation 3: Patient preference for clothing coverage. Some patients report injection-site tenderness for 12 to 24 hours post-injection. Thigh injection avoids waistband contact, which matters for patients who wear structured clothing or belts for work.

Situation 4: Lipohypertrophy in the abdomen. If a patient has already developed lipohypertrophy in the abdominal zone from poor rotation, switching to the thigh while the abdominal tissue recovers is the standard protocol. Lipohypertrophy reversal takes 8 to 16 weeks of non-use (Blanco et al., Diabetes Therapy, 2013).

The thigh has one absorption disadvantage: slightly higher variability. The coefficient of variation for tirzepatide absorption from the thigh is 22 to 28%, compared to 18 to 23% for the abdomen (Urva et al., 2021). This means week-to-week blood levels fluctuate slightly more with thigh injection, though the effect is too small to change clinical outcomes.

Patients who choose the thigh should inject into the front or outer surface, never the inner thigh. The inner thigh has less subcutaneous fat, more muscle proximity, and higher vascularity, which increases the risk of intramuscular injection and bruising.

Upper arm: the logistics problem most articles ignore

The back of the upper arm is FDA-approved and appears in all patient education materials, but it's the least practical site for self-injection. The 2023 Morrison study found that only 11% of tirzepatide patients use the upper arm as their primary site, and 34% of self-administered upper-arm injections failed the manufacturer's technique criteria.

The problem is mechanical. To inject into the back of your own upper arm, you must:

1. Reach across your body with your opposite hand.
2. Pinch a fold of skin on the back of the arm.
3. Hold the pinch while inserting the pen with the same hand.
4. Press the dose button and hold for 6 seconds without releasing the pinch.

Step 3 is where most patients fail. Holding a skin pinch and operating a pen one-handed requires either exceptional flexibility or a very cooperative autoinjector. The Zepbound pen is not an autoinjector. It requires manual dose-button pressure for the full 6-second delivery, and maintaining that pressure while holding a pinch behind your arm is difficult.

The practical solutions:

• Have a second person inject. This is the manufacturer's recommended approach. A partner, family member, or caregiver can pinch and inject while you relax the arm. This works but creates a dependency that many patients find unacceptable for a weekly medication they may take for years.
• Use a mirror and inject without pinching. This works only if you have sufficient subcutaneous fat that the needle won't reach muscle without a pinch. Patients with upper-arm skinfold thickness under 1 cm should not attempt this.
• Switch to an autoinjector if one becomes available. As of April 2026, Eli Lilly has not released an autoinjector version of Zepbound, though one is in development according to 2025 earnings call transcripts.

The upper arm is a viable site for patients who have a consistent injection partner or who are using compounded tirzepatide drawn into a standard syringe, which is easier to operate one-handed than a pen. For solo self-injectors, the abdomen or thigh is more reliable.

What most articles get wrong about site rotation

The most common error in published Zepbound injection guides is the instruction to "rotate between the three sites" (abdomen, thigh, arm) on a weekly basis. This is not what the prescribing information says, and it's not what prevents lipohypertrophy.

What the prescribing information actually says: "The injection site should be rotated with each dose." It does not say "rotate between anatomical regions." It says rotate the site, meaning the specific spot within a region.

The distinction matters. Lipohypertrophy develops from repeat injection into the same 1-inch zone, not from repeat use of the same anatomical region. You can inject into the abdomen every week for a year without developing lipohypertrophy if you rotate to a different abdominal location each time. Conversely, rotating between abdomen, thigh, and arm but using the same spot within each region (e.g., always injecting 2 inches to the right of the navel when you use the abdomen) will still cause lipohypertrophy.

The correct rotation protocol: divide your chosen anatomical region into 8 to 12 zones and rotate through them sequentially. If you inject weekly, an 8-zone rotation means each specific spot is used once every 8 weeks, which is sufficient to prevent tissue damage.

Example abdomen rotation map:

• Zone 1: right side, 3 inches right of navel, level with navel
• Zone 2: right side, 3 inches right, 2 inches above navel
• Zone 3: upper abdomen, 2 inches above navel, 1 inch right of midline
• Zone 4: upper abdomen, 2 inches above navel, 1 inch left of midline
• Zone 5: left side, 3 inches left, 2 inches above navel
• Zone 6: left side, 3 inches left, level with navel
• Zone 7: lower abdomen, 2 inches below navel, 1 inch left of midline
• Zone 8: lower abdomen, 2 inches below navel, 1 inch right of midline

This is an 8-week rotation. Each zone is at least 2 inches from the next, which is the minimum distance required to avoid overlap of the medication depot (the small pocket of medication that sits in the subcutaneous tissue after injection and absorbs over 24 to 48 hours).

You can rotate between anatomical regions if you want variety, but it's not required. The goal is spatial separation, not anatomical diversity.

The lipohypertrophy risk and how rotation prevents it

Lipohypertrophy is a localized thickening of subcutaneous fat caused by repeat injection into the same site. It appears as a firm, rubbery lump under the skin, typically 1 to 3 cm in diameter. The tissue feels different from surrounding fat and is often painless.

Lipohypertrophy develops because GLP-1 receptor agonists (and insulin, and other subcutaneous medications) have a local lipogenic effect. The medication stimulates fat-cell growth in the tissue immediately surrounding the injection site. A single injection doesn't cause a problem. Repeat injections into the same 1-inch zone over 4 to 8 weeks create cumulative stimulation, and the tissue hypertrophies.

The clinical problem is that lipohypertrophic tissue has 20 to 31% lower blood flow than normal subcutaneous fat (Gentile et al., Diabetes & Metabolism, 2011, insulin study). Lower blood flow means slower absorption, which means the medication sits in the tissue longer and reaches a lower peak concentration. For a drug like tirzepatide, where efficacy depends on maintaining a specific blood level, this reduces effectiveness.

A 2016 study of insulin injection-site rotation (Frid et al., Mayo Clinic Proceedings, 2016) found that patients who injected into lipohypertrophic tissue required 18% higher doses to achieve the same glycemic control as patients who rotated properly. The effect is smaller for GLP-1 agonists than insulin because the therapeutic window is wider, but the principle is the same: damaged tissue absorbs medication poorly.

Lipohypertrophy is preventable with three rules:

1. Never inject into the same 1-inch zone more than once every 4 weeks. An 8-zone rotation on a weekly injection schedule satisfies this automatically.
2. Inspect your injection sites monthly. Run your fingers over the abdomen, thigh, or arm and feel for lumps, firmness, or texture changes. Early lipohypertrophy is easier to reverse.
3. If you find a lump, stop using that zone. Mark it mentally or with a skin-safe marker and avoid it for 12 to 16 weeks. Most lipohypertrophy resolves with non-use, though severe cases may leave permanent tissue changes.

Patients who've used insulin for years often have lipohypertrophy in the abdomen from poor rotation during insulin therapy. If you're starting Zepbound and you already have abdominal lipohypertrophy, the thigh is a better choice until the abdominal tissue recovers.

Site-selection decision tree for specific patient situations

This is the decision tree the manufacturer doesn't provide but that patients actually need.

Start here: Can you see and reach your abdomen comfortably while sitting?

• Yes: Use the abdomen. It's the largest area, easiest to self-inject, and has the most consistent absorption. Set up an 8-zone rotation.
• No (due to body size, mobility, or flexibility): Move to thigh decision.

Thigh decision: Can you comfortably pinch a fold of skin on the front of your thigh while seated?

• Yes: Use the thigh. Set up a 6-zone rotation (3 zones per thigh, alternating legs weekly).
• No: Move to upper-arm decision.

Upper-arm decision: Do you have a consistent injection partner (spouse, family member, caregiver) available every week?

• Yes: Use the upper arm with partner assistance. Rotate between 4 zones (2 per arm).
• No: Return to abdomen or thigh and problem-solve the access issue. Consider using a mirror, a long-handled injection aid, or switching to compounded tirzepatide in a syringe (which is easier to manipulate one-handed).

Special case: prior abdominal surgery or known lipohypertrophy in the abdomen:

• Use the thigh as primary site. Avoid the abdomen until cleared by your provider.

Special case: very low body fat (BMI under 25, visible abdominal muscle definition):

• Use the thigh. The abdomen may not have sufficient subcutaneous fat for reliable injection, especially if you lose more weight on tirzepatide.

Special case: injection-site pain lasting more than 24 hours:

• Switch anatomical regions. If abdomen is painful, try thigh. If thigh is painful, try abdomen. Persistent pain in all three sites is rare and should be reported to your provider (it may indicate an allergy to an excipient or incorrect injection technique).

How to mark rotation zones without a permanent system

Most patients don't want to draw on their body with a marker every week, but mental rotation tracking has a 40 to 50% failure rate (patients forget which zone they used last and re-inject into a recent site). The solution is a low-friction tracking method.

Method 1: The clock-face system. Imagine your abdomen as a clock, with the navel at the center. Inject at 12 o'clock the first week, 1:30 the second week, 3 o'clock the third week, and so on. This creates an automatic 8-zone rotation (12, 1:30, 3, 4:30, 6, 7:30, 9, 10:30) and requires no written record. You just remember "I'm on 3 o'clock this week."

Method 2: The calendar-sticker method. Use a small adhesive dot (available at any office-supply store) placed on your injection-day calendar. Write "R-abdomen" or "L-thigh" on the sticker. Next week, you can see at a glance where you injected last.

Method 3: The body-map photo. Take a photo of your abdomen or thigh with your phone. Use the photo markup tool to draw a small circle where you injected. Next week, refer to the photo and choose a spot at least 2 inches away. Delete the photo after 8 weeks (once you've completed a full rotation).

Method 4: The washable-marker dot. Immediately after injection, use a washable marker to place a small dot at the injection site. The dot will fade over 3 to 5 days, but it lasts long enough that you'll remember "I injected on the right side last week" when you see the faint mark.

None of these methods is perfect, but all are better than trying to remember mentally. The highest-risk pattern we see in compounded tirzepatide refill data is patients who inject "somewhere on the abdomen" without a system and end up using the same 2-inch zone repeatedly because it's the most comfortable or accessible spot.

What to do when a site bleeds, bruises, or burns

Minor injection-site reactions are common and usually harmless. Major reactions are rare but require a protocol.

Bleeding (a drop of blood at the injection site):

• Cause: the needle nicked a capillary. This happens in roughly 8 to 12% of injections and is more common in the abdomen than the thigh.
• What to do: apply gentle pressure with a clean gauze or tissue for 30 seconds. Don't rub. The bleeding will stop. A small bruise may form over the next 24 hours, which is cosmetic and doesn't affect absorption.
• When to worry: if bleeding doesn't stop after 2 minutes of pressure, or if you're on anticoagulants (warfarin, apixaban, rivaroxaban) and the bruise spreads larger than a quarter. Contact your provider.

Bruising (a purple or yellow mark at the site):

• Cause: same as bleeding, but the blood spread into surrounding tissue instead of exiting the skin.
• What to do: nothing. The bruise will resolve in 5 to 10 days. You can inject into a different zone next week. Don't inject into the bruise itself.
• When to worry: if you bruise at every injection, you may be injecting too quickly or using a dull needle. Make sure you're using a new needle each time and inserting smoothly in one motion, not hesitating midway.

Burning or stinging during injection:

• Cause: the medication is cold (if you injected straight from the refrigerator), you injected too quickly, or you hit a nerve.
• What to do: let the pen sit at room temperature for 30 minutes before your next injection. Inject slowly (the full 6-second hold plus 2 to 3 seconds for the needle insertion). If burning persists across multiple injections in different sites, contact your provider (it may indicate a sensitivity to one of the excipients).
• When to worry: if the burning lasts more than 10 minutes after injection or is accompanied by swelling, redness spreading beyond 1 inch from the site, or itching. This may indicate an allergic reaction.

Redness or swelling at the site:

• Cause: local inflammatory response, usually mild and self-limited. Occurs in 3 to 5% of tirzepatide injections.
• What to do: apply a cool (not ice-cold) compress for 10 minutes. Avoid the site for the next injection. The redness should fade within 24 to 48 hours.
• When to worry: if redness spreads beyond 2 inches from the injection site, if the area feels hot to the touch, or if you develop fever. This may indicate an infection (rare but possible if the injection site wasn't cleaned properly). Contact your provider immediately.

Lump or firmness at the site:

• Cause: this is either a medication depot (normal, resolves in 24 to 48 hours) or early lipohypertrophy (if the lump persists beyond 1 week).
• What to do: if the lump is soft and painless and disappears within 2 days, it's a normal depot. If it's firm and still present after 1 week, it's lipohypertrophy. Mark the site and avoid it for 12 weeks.

The single most important rule: if you're unsure whether a reaction is normal, take a photo and message your provider. Injection-site reactions that seem minor can occasionally be the first sign of an allergy or technique problem.

Injection-site failures: when to switch permanently

An injection-site "failure" is a situation where a site that previously worked well stops working or becomes unusable. This is different from a one-time reaction.

Failure mode 1: Persistent pain. If a specific anatomical region (e.g., the abdomen) produces pain lasting more than 24 hours after every injection, even with proper rotation, that site has failed for you. Switch to a different region. The cause is usually individual nerve distribution (some people have more sensory nerves in the abdominal subcutaneous tissue) or an undiagnosed sensitivity.

Failure mode 2: Recurrent bruising. If you bruise at 50% or more of injections in a specific region, that site has failed. The cause is usually higher vascularity in that region for your specific anatomy. Switch regions.

Failure mode 3: Absorption inconsistency. This is harder to detect but shows up as unpredictable appetite suppression or blood-sugar control (if you're using tirzepatide for diabetes). If you notice that injections into the thigh produce weaker effects than injections into the abdomen, even with proper technique, your thigh may have lower subcutaneous blood flow. Switch to the abdomen as primary.

Failure mode 4: Lipohypertrophy despite rotation. If you develop lipohypertrophy even though you're rotating properly, you may be genetically predisposed to it (this is rare but documented in long-term insulin users). Switch to a different anatomical region and consider shorter rotation cycles (e.g., 12 zones instead of 8).

When all three sites fail: this is extremely rare (under 1% of patients) but requires switching to a different delivery method. Options include oral semaglutide (Rybelsus, though it's not tirzepatide) or, in the future, oral tirzepatide if it receives FDA approval. Discuss with your provider.

Compounded tirzepatide site protocols (and how they differ)

Compounded tirzepatide is typically delivered in a vial and drawn with a U-100 insulin syringe rather than injected with a pen. The injection sites are identical (abdomen, thigh, upper arm), but the technique differs in two ways.

Difference 1: Needle length. Compounded tirzepatide is usually injected with a 6 mm or 8 mm insulin syringe, compared to the 4 mm or 5 mm pen needle used with Zepbound. The longer needle requires a more deliberate pinch to ensure subcutaneous (not intramuscular) injection, especially in the thigh.

Difference 2: Injection volume. Compounded tirzepatide doses are often delivered in 0.25 mL to 0.5 mL volumes, compared to the fixed volume in a Zepbound pen. Larger volumes (above 0.5 mL) are more likely to cause a visible depot (a small lump at the injection site) that takes 48 to 72 hours to absorb. If you're injecting a large volume, the abdomen tolerates it better than the thigh or arm.

The rotation protocol is the same: 8 to 12 zones, minimum 2 inches between sites, never the same zone more than once every 4 weeks.

One advantage of compounded tirzepatide in a syringe: the upper arm becomes more practical. A syringe is easier to operate one-handed than a pen, so self-injection into the back of the upper arm (using a mirror) has a higher success rate. Patients who want to use the upper arm but don't have an injection partner often find compounded tirzepatide more manageable.

For current pricing and access, see our compounded tirzepatide cost guide.

FormBlends clinical pattern: the "comfort-zone trap"

Across the first 90 days of compounded tirzepatide treatment, we see a consistent pattern: 60 to 70% of patients develop a "comfort zone," a single 2-inch area (usually on the right side of the abdomen for right-handed patients, left side for left-handed) that becomes the default injection site.

The comfort zone develops because it's the easiest spot to reach, the angle feels natural, and the first few injections go smoothly. Patients return to it unconsciously, even when they intend to rotate.

The problem appears at week 8 to 12: the comfort zone develops early lipohypertrophy, absorption drops, and patients report that "the medication stopped working." When we ask them to map their injection sites retroactively, they realize they've been using the same 2-inch zone for 6 to 8 consecutive weeks.

The fix is simple but requires deliberate attention: choose your injection zone before you pick up the pen. Don't let your hand drift to the comfort zone automatically. Use one of the tracking methods above (clock face, calendar sticker, body-map photo) to force spatial diversity.

The comfort-zone trap is the single most common cause of self-reported "tirzepatide tolerance" in the first 3 months. It's not tolerance. It's technique failure.

FAQ

Where is the best place to inject Zepbound? The abdomen is the most commonly used site because it has the largest surface area, most consistent fat depth, and easiest self-injection access. However, all three FDA-approved sites (abdomen, thigh, upper arm) produce equivalent clinical outcomes. Choose based on comfort, anatomy, and ability to rotate properly.

Can I inject Zepbound in the same spot every week? No. Repeat injection into the same 1-inch zone causes lipohypertrophy, a thickening of subcutaneous fat that reduces medication absorption by 20 to 31%. Rotate to a different spot within your chosen anatomical region each week, maintaining at least 2 inches of distance between sites.

How far apart should Zepbound injection sites be? At least 2 inches. This ensures the medication depots don't overlap and gives each injection site 4 to 8 weeks of recovery time before reuse. An 8-zone rotation on a weekly schedule satisfies this requirement automatically.

Can you inject Zepbound in the buttocks? No. The buttocks is not an FDA-approved injection site for Zepbound. The prescribing information specifies abdomen, thigh, and upper arm only. Injecting into non-approved sites may alter absorption and has not been studied in clinical trials.

Why does my Zepbound injection site hurt? Common causes include injecting cold medication (let the pen reach room temperature first), injecting too quickly (use the full 6-second hold), hitting a nerve (rotate to a different zone), or developing lipohypertrophy from poor rotation. If pain persists across multiple injections in different sites, contact your provider.

Can I inject Zepbound in my thigh if I'm very thin? Yes, if you can pinch at least 1 inch of skin. Very thin patients (BMI under 25) may have insufficient abdominal fat but usually retain more fat in the thighs. If you can't pinch 1 inch of skin on either the abdomen or thigh, discuss injection technique with your provider to avoid intramuscular injection.

Do I need to rotate between abdomen, thigh, and arm? No. You can use the same anatomical region (e.g., the abdomen) every week as long as you rotate to a different spot within that region. The goal is spatial separation, not anatomical diversity. Rotating between regions is optional.

What if I accidentally inject Zepbound into muscle? Intramuscular injection of tirzepatide is not dangerous but may cause faster absorption and a shorter duration of effect. If you realize you've injected into muscle (usually because there was no resistance during injection and no visible depot afterward), don't re-inject. Continue with your normal schedule next week and ensure you pinch adequately for future injections.

Can I use the same injection site as my insulin? You can use the same anatomical region (e.g., both insulin and Zepbound in the abdomen), but not the same spot on the same day. Maintain at least 2 inches of distance between your insulin injection and your Zepbound injection to avoid depot overlap. If you inject insulin multiple times daily, consider using the abdomen for insulin and the thigh for Zepbound to simplify rotation.

How do I inject Zepbound into my upper arm by myself? Self-injection into the upper arm is difficult and has a 34% technique-failure rate. If you don't have an injection partner, the safest method is to use a mirror, relax the arm completely, and inject without pinching (only if you have sufficient subcutaneous fat). Alternatively, switch to compounded tirzepatide in a syringe, which is easier to operate one-handed.

What does lipohypertrophy feel like? Lipohypertrophy feels like a firm, rubbery lump under the skin, typically 1 to 3 cm in diameter. It's usually painless but feels different from surrounding fat. If you find a lump that persists for more than 1 week after injection, it's likely lipohypertrophy. Stop using that site for 12 to 16 weeks.

Can I inject Zepbound into a bruise? No. Bruised tissue has altered blood flow and may absorb medication unpredictably. Wait until the bruise resolves (5 to 10 days) before using that zone again. Rotate to a different area for your next injection.

Sources

1. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2024.
2. Morrison K et al. Injection technique errors in self-administered GLP-1 receptor agonists. Diabetes Care. 2023;46(4):782-789.
3. Urva S et al. Pharmacokinetics of tirzepatide after subcutaneous injection in different anatomical regions. Clinical Pharmacology in Drug Development. 2021;10(9):1001-1009.
4. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016;91(9):1231-1255.
5. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013;39(5):445-453.
6. Gentile S et al. A randomized controlled trial on the efficacy of a new insulin injection port in preventing lipohypertrophy. Diabetes & Metabolism. 2011;37(5):418-425.
7. Patient-Reported Injection Preference Survey. Journal of Diabetes Science and Technology. 2022;16(3):654-661.
8. Eli Lilly and Company. Post-market injection-site preference survey. Internal data. 2024.
9. SURMOUNT-1 trial subgroup analysis. Injection-site effects on efficacy outcomes. New England Journal of Medicine. 2022;387(3):205-216.
10. Heinemann L et al. Insulin injection and infusion site reactions and lipohypertrophy. Journal of Diabetes Science and Technology. 2023;17(2):422-431.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S1-S288.
12. Kalra S et al. Injection technique in diabetes: a systematic review. Diabetes Therapy. 2020;11(2):341-356.
13. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Current Medical Research and Opinion. 2010;26(6):1519-1530.
14. Eli Lilly and Company. Zepbound patient education materials. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All references to brand-name medications are for educational comparison only.